Status:

NOT_YET_RECRUITING

Research and Follow-up of the Determinants of the Progression and Complications of Inflammatory Bowel Diseases Treated or Not With Immunosuppressants.

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Collaborating Sponsors:

Sorbonne University

Conditions:

Crohn

Ulcerative Colitis (UC)

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Inflammatory Bowel Diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic, disabling conditions affecting young adults, marked by flare-ups and remissions. Traditional...

Detailed Description

Inflammatory Bowel Diseases (IBD) are chronic, disabling conditions that affect young adults with a predilection for flare-ups interspersed with periods of remission. Crohn's disease (CD) and ulcerati...

Eligibility Criteria

Inclusion

  • For all patients and control subjects
  • Person able to give free and informed consent.
  • Age ≥ 18 years.
  • Beneficiary of a social protection scheme or entitled person (excluding AME).
  • Consultation in the Gastroenterology and Nutrition Department of Saint-Antoine Hospital
  • Patients with IBD :
  • \- Patients with Crohn's disease or haemorrhagic rectocolitis with a diagnosis established or confirmed in the Gastroenterology and Nutrition Department at Saint-Antoine Hospital.
  • Microbiota control' subjects:
  • \- Healthy subjects seen in consultation as a preventive measure or as part of stool donations for FMT.
  • Endoscopy control' subjects:
  • \- Subjects with a medical indication for digestive endoscopy with biopsies:
  • For upper endoscopy: moderate upper digestive symptoms such as epigastralgia or pyrosis
  • For colonoscopy: moderate digestive symptoms suggestive of irritable bowel syndrome or screening for colorectal cancer.

Exclusion

  • For all patients and control subjects
  • Subjects under guardianship, curatorship or safeguard of justice.
  • Subjects who do not speak French.
  • IBD patients:
  • \- Colon preparation within 6 weeks before stool sampling (stool samples may be taken either before colonoscopy or at least 6 weeks afterwards).
  • Endoscopy control' and "microbiota control" subjects:
  • Subject suffering from a chronic disease
  • Antibiotics taken in the 6 weeks prior to endoscopy
  • Antibiotics or colonic preparation taken within 6 weeks prior to stool sampling (stool samples may be taken either before colonoscopy or at least 6 weeks afterwards).

Key Trial Info

Start Date :

September 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 1 2040

Estimated Enrollment :

4500 Patients enrolled

Trial Details

Trial ID

NCT07172945

Start Date

September 1 2025

End Date

November 1 2040

Last Update

September 15 2025

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Research and Follow-up of the Determinants of the Progression and Complications of Inflammatory Bowel Diseases Treated or Not With Immunosuppressants. | DecenTrialz